VCN 01

Drug Profile

VCN 01

Alternative Names: VCN-01

Latest Information Update: 30 Dec 2016

Price : $50

At a glance

  • Originator VCN Biosciences
  • Class Antineoplastics; Gene therapies; Oncolytic viruses
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Pancreatic cancer; Solid tumours

Most Recent Events

  • 29 Nov 2016 Adverse events, efficacy, pharmacokinetics and pharmacodynamics data from a phase I trial in Solid tumours presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR - 2016)
  • 01 Feb 2016 VCN Biosciences receives grant from MINECO Spanish Government for VCN 01 development in Retinoblastoma (In In neonates, infants, children, adolescents)
  • 01 Feb 2016 VCN Biosciences plans a clinical trial for Retinoblastoma (In neonates, infants, children, adolescents)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top